Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.

研究结果显示，慢性丙肝病人，TH1细胞活素表达显著并与肝免疫病理机制相关。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬化的慢性丙肝（CHC）患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。

The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.

肝纤维化不仅造成慢性肝炎、肝功能异常和影响愈后，而且是诸多慢性肝病向肝硬化发展的必经阶段。

Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛素抵抗和糖尿病是慢性丙型肝炎（CHC）中纤维化进展以及对抗病毒治疗无应答的危险因素。

It is used for chronic hepatitis, chronic gastricism, stomach and duodenum ulcer, neuralgia among ribs and neural functional disease.Efficacy: To replenish yin and soothe the depressed liver.

现代用于慢性肝炎、慢性胃炎、胃及十二指肠溃疡、肋间神经痛、神经官能症等属阴虚气滞者。